Format

Send to

Choose Destination
See comment in PubMed Commons below
Arch Neurol. 2005 Oct;62(10):1519-30.

Therapeutic considerations for disease progression in multiple sclerosis: evidence, experience, and future expectations.

Author information

1
Department of Ophthalmology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. elliot.frohman@utsouthwestern.edu

Abstract

In the management of patients with multiple sclerosis (MS), providers are all faced with the highly formidable challenge of ascertaining whether, and to what degree, disease-modifying therapy is effective in the individual patient. While much has been learned in randomized, controlled clinical trials, we cannot simply extrapolate the outcomes of these initiatives and apply them to the care of a single patient. In the future, the application of pharmacogenetic techniques, proteomics, and microarray analysis will yield novel profiling information on individual patients that will substantially refine the specific therapeutic questions of relevance: (1) What is the best treatment for an individual patient? (2) Which patients require intensive therapeutic combination regimens to optimize control of the disease process? (3) What are the appropriate drug dosing targets for an individual patient? and (4) Which patients will be predisposed to the development of drug-related adverse events? Such data may provide a novel variable of drug responsiveness that will mandate its inclusion into the process of covariate analyses for clinical trials.

PMID:
16216934
DOI:
10.1001/archneur.62.10.1519
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Silverchair Information Systems
    Loading ...
    Support Center